Polycystin-1 is required for insulin-like growth factor 1-induced cardiomyocyte hypertrophy
Access noteAcceso abierto
MetadataShow full item record
Cardiac hypertrophy is the result of responses to various physiological or pathological stimuli. Recently, we showed that polycystin-1 participates in cardiomyocyte hypertrophy elicited by pressure overload and mechanical stress. Interestingly, polycystin-1 knockdown does not affect phenylephrine-induced cardiomyocyte hypertrophy, suggesting that the effects of polycystin-1 are stimulus-dependent. In this study, we aimed to identify the role of polycystin-1 in insulin-like growth factor-1 (IGF-1) signaling in cardiomyocytes. Polycystin-1 knockdown completely blunted IGF-1-induced cardiomyocyte hypertrophy. We then investigated the molecular mechanism underlying this result. We found that polycystin-1 silencing impaired the activation of the IGF-1 receptor, Akt, and ERK1/2 elicited by IGF-1. Remarkably, IGF-1-induced IGF-1 receptor, Akt, and ERK1/2 phosphorylations were restored when protein tyrosine phosphatase 1B was inhibited, suggesting that polycystin-1 knockdown deregulates this phosphatase in cardiomyocytes. Moreover, protein tyrosine phosphatase 1B inhibition also restored IGF-1-dependent cardiomyocyte hypertrophy in polycystin-1- deficient cells. Our findings provide the first evidence that polycystin-1 regulates IGF-1- induced cardiomyocyte hypertrophy through a mechanism involving protein tyrosine phosphatase 1B.
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT) CONICYT FONDECYT FONDECYT 1180613 1200490 3210443 3190546 REDES170032 FONDAP 15130011 American Heart Association CDA 19CDA34680003 Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
Artículo de publícación WoS
Quote ItemPlos One August 18, 2021
The following license files are associated with this item: